Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536775 | 1.00 | PSMD14 (0.41) | PSMD14HSP90AA1MMP2MC4RRAD52 | |
| SCHEMBL8217828 | 0.98 | HTR7 (0.39) | PSMD14HSP90AA1MMP2MC4RRAD52 | |
| SCHEMBL22649183 | 0.98 | HTR7 (0.39) | PSMD14HSP90AA1MMP2MC4RRAD52 | |
| SCHEMBL9232425 | 0.92 | HTR7 (0.40) | HTR7ALDH1A1HPGD | |
| SCHEMBL9278852 | 0.92 | HTR7 (0.40) | HTR7ALDH1A1HPGD | |
| SCHEMBL9137197 | 0.90 | SLC2A1 (0.44) | SLC2A1NR1I2 | |
| SCHEMBL6684351 | 0.90 | SLC2A1 (0.44) | SLC2A1NR1I2 | |
| SCHEMBL6678858 | 0.88 | OPRM1 (0.44) | SLC2A1NR1I2 | |
| SCHEMBL20178582 | 0.85 | SLC2A1 (0.39) | SLC2A1NR1I2ALDH1A1 | |
| SCHEMBL9137103 | 0.84 | EPHX1 (0.45) | SLC2A1NR1I2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | PSMD14 3447/4885HSP90AA1 3125/4885MMP2 742/4885 |
| US-10813934-B2 | Sirtuin modulators as inhibitors of cytomegalovirus | SIRT1, SIRT2, SIRT7 | PSMD14 2707/4885HSP90AA1 308/4885MMP2 2314/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | PSMD14 3447/4885HSP90AA1 3125/4885MMP2 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.